Markets:

Overview

News

Currencies

International

Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ:HZNP)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Will Investors Notice Exciting Sign On Horizon Therapeutics's Chart? ↗

April 28, 2022

If history is any guide, there may be good fortune ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

Eton Pharmaceuticals Names James Gruber Finance Chief ↗

April 11, 2022

Eton Pharmaceuticals Inc (NASDAQ: ETON) has appointed James Gruber as Chief Financial Officer effective immediately. He succeeds Wilson Troutman, who is retiring....

Via Benzinga

Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors ↗

April 09, 2022

Raytheon and Shell are just below buy points. They have good company.

Via Investor's Business Daily

Executives Sell More Than $262M Of 5 Stocks ↗

April 04, 2022

Although gold futures traded higher on Monday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗

March 15, 2022

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...

Via Benzinga

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

Horizon Therapeutics Stock Shows Market Leadership; Earns 82 RS Rating ↗

March 08, 2022

Looking for the best stocks to buy? Horizon Therapeutics stock fits that bill with its Relative Strength Rating upgraded to 82.

Via Investor's Business Daily

Horizon Therapeutics Earnings Perspective: Return On Capital Employed ↗

March 04, 2022

Pulled from Benzinga Pro data, Horizon Therapeutics (NASDAQ:HZNP) posted Q4 earnings of $173.18 million, an increase from Q3 of 46.97%. Sales dropped to $1.01 billion, a 2.22%...

Via Benzinga

Horizon Therapeutics' Q4 Earnings Beat Expectation As Tepezza, Krystexxa Boost Sales ↗

March 01, 2022

Horizon Therapeutics plc's (NASDAQ: HZNP) Q4 sales increased 36% Y/Y to $1.014 billion, beating the consensus of $995.87 million. The adjusted gross profit declined...

Via Benzinga

Horizon Therapeutics: Q4 Earnings Insights ↗

March 01, 2022

Horizon Therapeutics (NASDAQ:HZNP) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗

March 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Insider Buying Detected – Buy This Biotech Now ↗

February 23, 2022

Biotech and pharmaceutical research are the hottest growing sectors in the global business market, brought into the public eye by the onset of the COVID-19 pandemic.

Via Talk Markets

Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation ↗

February 16, 2022

Horizon Therapeutics plc (NASDAQ: HZNP) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis...

Via Benzinga

Death Cross Looms Over Horizon Therapeutics Investors ↗

January 26, 2022

If history is any guide, there may be trouble ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "death cross" has formed on its chart and, not surprisingly,...

Via Benzinga

7 of the Top-Rated Pharmaceutical Stocks for Q1 ↗

January 18, 2022

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks.

Via InvestorPlace

This Biotech CEO Is Trying To Cure His Son's Rare Disease ↗

December 09, 2021

Few questions stump Tim Walbert. But the Horizon Therapeutics CEO is still working to answer one of them from his son.

Via Investor's Business Daily

7 Drug Stocks to Buy Now While They’re Still on Sale ↗

November 30, 2021

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead.

Via InvestorPlace

Topics Supply Chain

Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗

December 08, 2021

Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...

Via Benzinga

Horizon Therapeutics's Return On Capital Employed Insights ↗

November 04, 2021

According to Benzinga Pro, during Q3, Horizon Therapeutics (NASDAQ:HZNP) earned $331.54 million, a 142.86% increase from the preceding quarter. Horizon Therapeutics also posted a...

Via Benzinga

Horizon Pharma plc (HZNP) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

HZNP earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

Stock Market Rally Keeps Running On Tesla, Nvidia, Fed Decision, Jobs Report: Weekly Review ↗

November 05, 2021

But the Nasdaq is starting to look extended.

Via Investor's Business Daily

Topics Bonds Economy Stocks

CFO Retirement Plan Undoes Horizon Therapeutics Stock After Beat-And-Raise ↗

November 03, 2021

Chief Financial Officer Paul Hoelscher will retire on May 16.

Via Investor's Business Daily

Topics Retirement

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Beam Therapeutics Stock Flashes Renewed Technical Strength ↗

October 12, 2021

On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before.

Via Investor's Business Daily

Innoviva Stock In Buy Range; Joins Ranks Of Top-Performing Stocks With Strength Ratings Over 90 ↗

October 08, 2021

Innoviva stock is within a buy range after climbing above a 16.82 entry in a flat base. The proper buying range is up to 5% above the entry.

Via Investor's Business Daily

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Alkermes Stock Composite Rating Rises To Near-Perfect 96 As It Posts Erratic But Huge Sales Gains ↗

October 05, 2021

The IBD SmartSelect Composite Rating for Alkermes rose from 94 to 96 Tuesday.

Via Investor's Business Daily

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ:HZNP)

Headline News about Horizon Therapeutics Public Limited Company - Ordinary Shares

Starting at $3.75/week.

Subscribe Today